Regulation of the gut microbiome using probiotics such as Lactobacillus spp. is recently focused on as one of the preventive measures for allergy. We originally isolated Lactobacillus sp. (L. AZABU) from the healthy dog guts. We here evaluated the anti-allergic effects of L. AZABU using hapten-induced atopic dermatitis (AD) and asthma mouse models. First, daily oral administration of live L. AZABU (2×10⁸ CFU/ml) during the experimental period significantly prevented the development of AD symptoms, skin thickness, and trans-epidermal water loss in the AD mouse model. Significant decreased number of IgE-positive B cells in auricular lymph node was also observed in L. AZABU treatment group, indicating allergen-specific immunoreaction was regulated by L. AZABU. Group 2 innate lymphoid cells, which play a pivotal role in non-allergen-specific immunoreaction, also significantly suppressed by oral administration of live L. AZABU. Next, the anti-allergic effects of live L. AZABU was simultaneously demonstrated in the asthma mouse model, including significant decrease of inflammatory pathological change of lung, and both allergen-specific and non-specific immunoreaction in hilar lymph node and lung tissue. Our findings suggested that live L. AZABU has anti-allergic properties although the mechanism of action is still being investigated.